Amneal Pharmaceuticals reports Q4 adjusted EPS 21c, consensus 18c

Reports Q4 revenue $814M, consensus $807.32M. “We are extremely pleased with Amneal’s sixth consecutive year of consistent execution and strong growth. Our full year 2025 performance highlights the durability of our diversified portfolio and the successful execution of our strategy. In Specialty, CREXONT continues to see strong uptake, and we successfully launched our newest branded product, the BREKIYA autoinjector. In Affordable Medicines, we delivered a robust cadence of new product approvals, including our first two inhalation products and our fourth and fifth biosimilars. Looking ahead, we believe Amneal is very well positioned to deliver substantial growth and create long-term value for years to come,” said Chirag and Chintu Patel, Co-Chief Executive Officers.